Patents by Inventor Tomoko Yasuhiro

Tomoko Yasuhiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLO PYRIMIDINE DERIVATIVE
    Publication number: 20160264579
    Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 15, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO, Mark Allan WOLF, Vijay Dattaram PAWAR, Anjan CHAKRABARTI, Santhosh Kumar CHITTIMALLA
  • QUINOLINE DERIVATIVE
    Publication number: 20160168121
    Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 16, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
  • COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITOR
    Publication number: 20150125446
    Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 7, 2015
    Inventors: Christian Klein, Toshio Yoshizawa, Tomoko Yasuhiro